Increased concentrations of VPO1 are consistent among pre-clinical studies addressing cardiovascular disorders, but it is currently unclear whether an elevated level of circulating VPO1 accompanies severity of commonly available clinical markers of CVRF, in humans. The gene discussed is PXDN; the disease is cardiovascular disorder.